Press "Enter" to skip to content

Pfizer Tumbles After Abandoning Weight-Loss Pill

By Tyler Durden

With shares already reflecting a post-COVID dearth of revenue streams, Pfizer’s growth outlook just took another hit as it halted development of its experimental weight-loss pill after a high rate of side effects appeared in a mid-stage study.

More than half of patients in the study had to stop taking danuglipron due to nausea and vomiting, according to a statement Friday.

Read Full Article Here…(

Home | Caravan to Midnight (

Live Stream + Chat (

We Need Your Help to Keep Caravan To Midnight Going,

Please Consider Donating to Help Keep Independent Media Independent

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Breaking News: